Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78436735 After Two Doses of BNT162b2 vaccine in Solid Organ Transplant Recipients.

IF 3.3 4区医学 Q3 IMMUNOLOGY Immunology letters Pub Date : 2025-01-09 DOI:10.1016/j.imlet.2024.106968

Yoichiro Natori, Eric Martin, Adela Mattiazzi, Leopoldo Arosemena, George William Burke, Mrudula R Munagala, Suresh Manickavel, Katherine Sota, Suresh Pallikkuth, Jessie Chen, Julia Bini, Jacques Simkins, Shweta Anjan, Rodrigo M Vianna, Giselle Guerra

{"title":"Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78436735 After Two Doses of BNT162b2 vaccine in Solid Organ Transplant Recipients.","authors":"Yoichiro Natori, Eric Martin, Adela Mattiazzi, Leopoldo Arosemena, George William Burke, Mrudula R Munagala, Suresh Manickavel, Katherine Sota, Suresh Pallikkuth, Jessie Chen, Julia Bini, Jacques Simkins, Shweta Anjan, Rodrigo M Vianna, Giselle Guerra","doi":"10.1016/j.imlet.2024.106968","DOIUrl":null,"url":null,"abstract":"Introduction: In Solid Organ Transplant (SOT) recipients, due to immunosuppression, the immunogenicity after COVID-19 vaccination is suboptimal and its durability is unknown.Methods: We conducted a post-hoc analysis of a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs JNJ-78436735 as the third dose after two doses of BNT162b2 in adult SOT recipients with active graft to compare long-term immunogenicity.Results: Forty-one recipients were analyzed. Median IgG levels against SARS-CoV-2 at 6 months were 53,747 (range 949 - 657,558) and 7,632 (range 642 - 672,000) AU/ml for BNT162b2 vs JNJ-78436735, respectively (p=0.017). The median geometric mean fold increase ratio at 6 months was 37.2 (0.12-618.5) and 4.30 (0.1-204.2) for BNT162b2 vs JNJ-78436735, respectively (p<0.05). After two doses of BNT162b2, homologous approach with BNT162b2 achieved a superior immunogenicity compared to heterologous approach with JNJ-78436735.Conclusion: In this post hoc analysis, we report durability of specific IgG between two vaccine strategies and found no statistically significant difference between two groups. (Clinical Trial Registry: NCT05047640).","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":" ","pages":"106968"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.imlet.2024.106968","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In Solid Organ Transplant (SOT) recipients, due to immunosuppression, the immunogenicity after COVID-19 vaccination is suboptimal and its durability is unknown.

Methods: We conducted a post-hoc analysis of a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs JNJ-78436735 as the third dose after two doses of BNT162b2 in adult SOT recipients with active graft to compare long-term immunogenicity.

Results: Forty-one recipients were analyzed. Median IgG levels against SARS-CoV-2 at 6 months were 53,747 (range 949 - 657,558) and 7,632 (range 642 - 672,000) AU/ml for BNT162b2 vs JNJ-78436735, respectively (p=0.017). The median geometric mean fold increase ratio at 6 months was 37.2 (0.12-618.5) and 4.30 (0.1-204.2) for BNT162b2 vs JNJ-78436735, respectively (p<0.05). After two doses of BNT162b2, homologous approach with BNT162b2 achieved a superior immunogenicity compared to heterologous approach with JNJ-78436735.

Conclusion: In this post hoc analysis, we report durability of specific IgG between two vaccine strategies and found no statistically significant difference between two groups. (Clinical Trial Registry: NCT05047640).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

事后分析：实体器官移植受者第三剂BNT162b2与两剂BNT162b2疫苗后JNJ-78436735的6个月免疫原性

导言：在实体器官移植（SOT）受者中，由于免疫抑制，COVID-19疫苗接种后的免疫原性并不理想，其持久性也未知：方法：我们对一项患者盲法、单中心、随机对照试验进行了事后分析，比较了BNT162b2与JNJ-78436735作为第三剂接种BNT162b2后的长期免疫原性：对41名受者进行了分析。6 个月时，BNT162b2 与 JNJ-78436735 抗 SARS-CoV-2 IgG 的中位数分别为 53,747 AU/ml（949 - 657,558 AU/ml）和 7,632 AU/ml（642 - 672,000 AU/ml）（p=0.017）。在 6 个月时，BNT162b2 与 JNJ-78436735 的几何平均折增比中位数分别为 37.2（0.12-618.5）和 4.30（0.1-204.2）（p结论：在这项事后分析中，我们报告了两种疫苗策略之间特异性 IgG 的耐久性，发现两组之间没有统计学意义上的显著差异。(临床试验登记：NCT05047640）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Immunology letters 医学-免疫学

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

44 days

期刊介绍： Immunology Letters provides a vehicle for the speedy publication of experimental papers, (mini)Reviews and Letters to the Editor addressing all aspects of molecular and cellular immunology. The essential criteria for publication will be clarity, experimental soundness and novelty. Results contradictory to current accepted thinking or ideas divergent from actual dogmas will be considered for publication provided that they are based on solid experimental findings. Preference will be given to papers of immediate importance to other investigators, either by their experimental data, new ideas or new methodology. Scientific correspondence to the Editor-in-Chief related to the published papers may also be accepted provided that they are short and scientifically relevant to the papers mentioned, in order to provide a continuing forum for discussion.